glp 1 receptor agonists canada GLP-1 Agonist Market Size & Outlook, 2033 Frontiers | GLP-1 Receptor Agonists:
Description
54 In another phase 2 trial done to evaluate the efficacy of orforglipron in adults with obesity without diabetes, it was found to lead to significant weight reduction compared to placebo
Gentile S, Strollo F, Ceriello A, Group A-OITS
Although, at first glance, it is easy to overestimate the findings and assume they apply to everyone, this studys participants were a very specific group: older adults with type 2 diabetes
In a retrospective cohort study, the researchers used data of 27 279 patients with type 2 diabetes and stage 5 CKD or ESKD from the National Health Insurance Research Database of Taiwan
doi: 10.3233/jad-2002-4605
Key drugs and the evidence that stunned clinicians Several GLP-1 RAs and related agents have been studied for weight management
